Zurich Cantonal Bank’s KalVista Pharmaceuticals KALV Stock Holding History

Zurich Cantonal Bank’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$489K	Buy	+24,296	New	+$392K	﹤0.01%	1842
2025 Q4	–	Sell	-4,545	Closed	-$60.2K	–	3044
2025 Q3	$55.4K	Buy	+4,545	New	+$62.8K	﹤0.01%	2445
2025 Q1	–	Sell	-1,164	Closed	-$9.86K	–	2659
2024 Q4	$9.86K	Sell	1,164 -247	-18%	-$2.56K	﹤0.01%	2607
2024 Q3	$16.3K	Sell	1,411 -25	-2%	-$314	﹤0.01%	2604
2024 Q2	$16.9K	Sell	1,436 -64	-4%	-$747	﹤0.01%	2595
2024 Q1	$17.8K	Buy	+1,500	New	+$20K	﹤0.01%	2634
2022 Q1	–	Sell	-3,085	Closed	-$41K	–	2782
2021 Q4	$41K	Sell	3,085 -313	-9%	-$4.98K	﹤0.01%	2786
2021 Q3	$59K	Buy	3,398 +88	+3%	+$1.78K	﹤0.01%	2568
2021 Q2	$79K	Buy	3,310 +138	+4%	+$3.61K	﹤0.01%	2314
2021 Q1	$81K	Buy	+3,172	New	+$83.3K	﹤0.01%	2236

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zurich Cantonal Bank's KALV Position: Q1 2026 in Review

Zurich Cantonal Bank opened a new position in KalVista Pharmaceuticals (KALV) in Q1 2026: 24,296 shares worth $489K. The stake represents ﹤0.01% of the portfolio and ranks #1842 among its holdings. This is a return to the name: Zurich Cantonal Bank previously reported a position in KALV as recently as Q3 2025.

Zurich Cantonal Bank first reported a position in KALV in Q1 2021 and has held it in 10 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Zurich Cantonal Bank held 24,296 shares of KalVista Pharmaceuticals worth $489K as of Q1 2026.
KalVista Pharmaceuticals was a new Zurich Cantonal Bank position in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q1 2026, its #1842 holding.
Zurich Cantonal Bank first reported a position in KalVista Pharmaceuticals in Q1 2021 and has held it in 10 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Zurich Cantonal Bank's 13F filing for Q1 2026, filed 15 May 2026.